Marine Compound Xyloketal B Reduces Neonatal Hypoxic-Ischemic Brain Injury

作者：Xiao, Ai-Jiao; Chen, Wenliang; Xu, Baofeng; Liu, Rui; Turlova, Ekaterina; Barszczyk, Andrew; Sun, Christopher Lf; Liu, Ling; Deurloo, Marielle; Wang, Guan-Lei; Feng, Zhong-Ping^*; Sun, Hong-Shuo

来源：Marine Drugs, 2015, 13(1): 29-47.

DOI：10.3390/md13010029

• hypoxic-ischemic injury
• infarct volume
• neuroprotection
• oxygen glucose deprivation
• primary neuronal cell culture
• neonatal stroke
• behavioral tests
• marine drug

Neonatal hypoxic-ischemic encephalopathy causes neurodegeneration and brain injury, leading to sensorimotor dysfunction. Xyloketal B is a novel marine compound isolated from a mangrove fungus Xylaria species (no. 2508) with unique antioxidant effects. In this study, we investigated the effects and mechanism of xyloketal B on oxygen-glucose deprivation-induced neuronal cell death in mouse primary cortical culture and on hypoxic-ischemic brain injury in neonatal mice in vivo. We found that xyloketal B reduced anoxia-induced neuronal cell death in vitro, as well as infarct volume in neonatal hypoxic-ischemic brain injury model in vivo. Furthermore, xyloketal B improved functional behavioral recovery of the animals following hypoxic-ischemic insult. In addition, xyloketal B significantly decreased calcium entry, reduced the number of TUNEL-positive cells, reduced the levels of cleaved caspase-3 and Bax proteins, and increased the level of Bcl-2 protein after the hypoxic-ischemic injury. Our findings indicate that xyloketal B is effective in models of hypoxia-ischemia and thus has potential as a treatment for hypoxic-ischemic brain injury.

• 出版日期2015-1
• 单位河北医科大学; 中山大学